Position in GH
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$738,960
-$10,394,300 QoQ
Shares Held
8,000
-92.7% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in GH Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026FARALLON CAPITAL MANAGEMENT LLC holds $1,312,288,955 across 9 Diagnostics & Research names. GH ranks #5 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NTRA |
Natera, Inc.
|
3,207,366 | $641,441,126 | |
| 2 | TMO |
Thermo Fisher Scientific Inc.
|
881,485 | $433,276,322 | |
| 3 | GRAL |
GRAIL, Inc.
|
3,253,684 | $168,150,389 | |
| 4 | TWST |
Twist Bioscience Corp
|
1,427,650 | $67,841,928 | |
| 5 | GH |
Guardant Health, Inc.
This page
|
8,000 | $738,960 | |
| 6 | WGS |
GeneDx Holdings Corp.
|
5,000 | $321,100 | |
| 7 | VCYT |
Veracyte, Inc.
|
7,000 | $225,470 | |
| 8 | ADPT |
Adaptive Biotechnologies Corp
|
11,000 | $152,680 |
All Filings in GH
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $738,960 | 8,000 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $11,133,260 | 109,000 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $499,840 | 8,000 | Shares | Other | 2026-02-17 | |
| 2025-06-30 | $416,320 | 8,000 | Shares | Other | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||